AdaptivCRT Algorithm Linked to Reduction in Readmissions
Decreased 30-day readmission rates in patients with heart failure or all-cause index hospitalization
MONDAY, June 15, 2015 (HealthDay News) -- For patients with heart failure or all-cause index hospitalization, cardiac resynchronization therapy (CRT) devices equipped with the Medtronic AdaptivCRT (aCRT) algorithm correlate with a reduction in 30-day readmission, according to a study published online June 10 in JACC: Heart Failure.
Randall C. Starling, M.D., M.P.H., from the Cleveland Clinic, and colleagues examined the impact of aCRT on 30-day readmissions after heart failure and all-cause index hospitalizations using data from the Adaptive CRT trial. Patients were randomized to aCRT (318 patients) or CRT with echocardiographic-optimization (Echo; 160 patients). Patients were followed for a mean of 20.2 months. The proportion of heart failure and all-cause hospitalizations that had readmission within 30 days was compared.
The researchers found that the 30-day readmission rate was 19.1 percent in the aCRT group and 35.7 percent in the Echo group for heart failure (odds ratio, 0.41). The corresponding 30-day readmission rates were 14.8 versus 24.8 percent, for all-cause hospitalization (odds ratio, 0.54). Beyond 30 days there was also a significant reduction in the risk of readmission following heart failure or all-case index hospitalization with aCRT.
"aCRT is associated with a significant reduction in the probability of a 30-day readmission following both heart failure and all-cause hospitalizations," the authors write.
Several authors disclosed financial ties to Medtronic, which funded the study.